Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb – Research Grade

Description of Nelistotug Biosimilar - Anti-Cell surface antigen CD96 mAb - Research Grade

Introduction

Nelistotug Biosimilar is a type of therapeutic antibody that targets the cell surface antigen CD96. This biosimilar is a research grade product that has been developed for use in laboratory studies and pre-clinical trials. In this article, we will explore the structure, activity, and potential applications of Nelistotug Biosimilar in the field of immunology.

Structure of Nelistotug Biosimilar

Nelistotug Biosimilar is a monoclonal antibody, meaning it is produced from a single clone of immune cells. It is designed to mimic the structure of the original antibody, anti-CD96 mAb, which is a fully humanized monoclonal antibody. This means that the antibody is made up of human-derived components, reducing the risk of immune reactions in patients.

The structure of Nelistotug Biosimilar is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of four constant regions and one variable region, while the light chains have two constant regions and one variable region. The variable regions are responsible for binding to the target antigen, CD96, while the constant regions determine the antibody’s effector functions.

Activity of Nelistotug Biosimilar

Nelistotug Biosimilar works by specifically binding to the cell surface antigen CD96. This antigen is found on the surface of various immune cells, including T cells, natural killer cells, and dendritic cells. CD96 is known to play a role in regulating immune responses, and its overexpression has been linked to various autoimmune diseases and cancer.

By binding to CD96, Nelistotug Biosimilar can block its activity and prevent it from interacting with its ligand, CD155. This disrupts the signaling pathway of CD96 and can potentially modulate immune responses. Additionally, Nelistotug Biosimilar can also trigger antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cells expressing CD96.

Applications of Nelistotug Biosimilar

The primary application of Nelistotug Biosimilar is in the field of immunology, particularly in the study of CD96 and its role in immune regulation. This biosimilar can be used in laboratory experiments to investigate the effects of blocking CD96 on immune cells and its potential therapeutic benefits.

Nelistotug Biosimilar also has potential in the treatment of autoimmune diseases and cancer. By targeting CD96, this biosimilar can potentially suppress overactive immune responses in autoimmune diseases and enhance immune responses against cancer cells. Pre-clinical studies have shown promising results in animal models, and further research is needed to determine its efficacy and safety in human patients.

In addition to its therapeutic applications, Nelistotug Biosimilar can also be used as a diagnostic tool. CD96 is known to be overexpressed in certain diseases, and measuring its levels in patient samples can provide valuable information for disease diagnosis and monitoring.

Conclusion

In summary, Nelistotug Biosimilar is a research grade therapeutic antibody that targets the cell surface antigen CD96. Its structure mimics that of the original antibody, anti-CD96 mAb, and it works by blocking CD96 activity and triggering immune-mediated cytotoxicity. This biosimilar has potential applications in immunology, autoimmune diseases, cancer, and diagnostics. Further research and clinical trials are needed to fully evaluate its efficacy and safety in human patients.